Earnings call transcript Q4 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon everyone and welcome to the Ardelyx Fourth Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, today's event is being recorded.

And at this time, I'd like to turn the floor over to Caitlin Lowie, Vice President, Corporate Communications and Investor Relations.

You may begin.

Caitlin Lowie

you. Thank and fourth everyone call. financial to welcome afternoon quarter our results Good

section website this to is today, Investors refer we available the press the During will earlier the call, ardelyx.com. at release issued in of company’s which

forward-looking During subject that to be are uncertainties. statements this and will call, we making risks

on from also may XX-K website recent encourage annual our on described. Form you be in to actual results those factors most Our review today, our can which filed found differ materially ardelyx.com. We our risk at report

While future, elect our to so obligation in we update may if these we to statements forward-looking views even any the change. specifically disclaim do

look Our begin overview ahead today's President and will progress an Mike of remarks and Raab call the with a during to CEO, XXXX. opening company's with XXXX

provide to launch support as on Officer, Rodriguez, launch the Susan IBSRELA, successful activities Commercial Chief approved. well Next, preparation if an update as XPHOZAH will of of

will financial and Renz, the December remarks company's the year full Officer, Chief XXst, with Financial of ended XXXX. conclude Justin performance quarter today's and review formal Operations fourth during a

Chief Laura Rosenbaum, Officer; for Assurance question-and-answer will us Chief Officer; and Regulatory Medical and Dr. Officer join David Blanks, Quality period. Williams, session the Affairs Rob Dr. Chief Development

call the to With me that, let pass Mike. over

Mike Raab

have on the afternoon on Thank on to I we provide tremendous our great our the XPHOZAH you, an path bring patients IBSRELA Caitlin a made good is everyone. that progress update and to It pleasure that dialysis. launch and

captured Ardelyx of tenacity part will over XPHOZAH, today well healthcare about The patient supporters hard the it's on of last in for our many be XPHOZAH. as progress To and the and the and entire well of dedication, not is IBSRELA clear, the results about our as just the decade communities. provider Justin, Ardelyx team discuss a work, Susan, and I year

the vision plans during patients everyone bringing work realize our of of continued commitments products demonstrates hard ability our most importantly, novel of on the execute our challenge in midst the And of and mechanism pandemic, it to In faced our profound all a need. to illustrates success doing Ardelyx. to

but medical develop -- innovative unmet is We discover, needs. say significant first-in-class mission develop, commercialize that medicines meet this often, and to our

in a biotech isn't of and the we especially of missions, our a Many and once can in important but it medicine we that the year. of to it similar potential to awesome have have patients goals path another again with later company, us size, do say that at done are bringing company this

IBSRELA, our we patients with prescriptions refill patients much demonstrating year, with March for in both syndrome constipation IBS-C. relief needed irritable bringing and with therapy, prescription novel last In significant of and bowel first new we're launched quarter-over-quarter growth to and

raising as use IBSRELA, In our December noted update, their of reported either that surveyed GIs high. XX% or satisfaction of with moderate treatment the Spherix

and In providing report commercial the an they to report itself benefits intent addition, patients to meaningful is GIs IBSRELA clinically establishing within non-using XX% of company. IBSRELA three -- months. surveyed next Ardelyx a in as adopt is the

then positive an which Cardiorenal the and the overwhelmingly supporting to Committee Cardiorenal XPHOZAH. experienced XPHOZAH, Advisory the with division last addition, In an us work benefit appeal label instructing followed New quarter, of of was our granting we on for vote Drugs, Office by appropriate

meeting and of the a appreciative really We and we mid-February, very a FDA. with was our Cardiorenal discussion in we resubmission, time and positive NDA are It held quickly A division. moving responsiveness the towards the Type of are

NDA work quarter. our completing for XPHOZAH track resubmission and We on are for are on second early in the now the

in II will a could review. or that course the month year Regardless, and if be to are of this Class that second our six be As half said we it shorter. launch are before, approved. well-positioned we expectations have of base We this case will be hopeful ready

things As to to to moment, updates able In date review we appraise the I'm any a other goal walk will through you are over the the share. Susan call and with going progress, we momentum continues to to is planning into What call XPHOZAH. our that is momentum. activities and gain growing that from go-to market away I want take IBSRELA for IBSRELA is built commercial important today's you to hand and

are that would X achieving When least today, could of nothing we to mid Based million million. of on which at we that are high we prescription I its expect launch IBSRELA, we the that $XXX there's on we what of revenue IBS-C single-digit its that yield seeing way announced we target. a peak our capture And believe share shared market, expected changes we perspective.

is I confidence XPHOZAH team mobilizing have launch and that to if Importantly, also ready to want approved. Ardelyx the you

a and that to discovery I our a expands we replicable. and a our important that are strategy therapeutics on continue of Finally, want to unique that that commercial we aspect and behind reinforce accomplish, business critical the crucial are is development and dream with generating. innovative approach is we are what With that is demonstrating Ardelyx company executing of results an we

have first-in-class patients. therapies, benefits which meaningful We demonstrating developed strong clinical data for

therapeutic is in a persistent and are where significant medical need. areas there We unmet

specialist very in are expect our XPHOZAH We for similar efforts with market follow with dynamic. healthcare will large a providers executing and IBSRELA concentrated established commercialization of a set we

property intellectual horizon. leadership to commercial agents continue a the strong team that new have on we highly of disruptive have And long with branded experienced drive results. led strategy will commercial runway an by no We innovative,

is have both IBSRELA first-in-class true our agents, portfolio and current we What XPHOZAH. for

expand IBSRELA, next phase XPHOZAH, growth execute we We to plans as our will will and seek to the support successful our strategy our of for momentum of build to businesses launch commercial growth. leverage this on the we for continue

the to turn over Susan? call that, With I'll Susan.

Susan Rodriguez

topics review year performance are you, Thank that market we be establishing continued gain. will and today. gaining, for strong are position Mike. reviewing several and I'll QX full IBSRELA, our will share enable traction I we

established XXXX. will IBSRELA take strategy. then this have and launch favorable to of time opportunity year, our preparations that some our XPHOZAH, in the for foundational of second drivers, cover launch growth for strong go-to-market half will a review uptake I I in the for predicted key momentum achievements

So, let's begin IBSRELA. with

Our revenue QX in $X.X to our revenue came of our This going from in million momentum sales of through at IBSRELA the $X.XX representing $X.X for QX million. XXXX revenue March a increase of with year launch total million, IBSRELA brings XX% into XXXX. growth for strong the end versus

and IBSRELA adoption an launch early data results novel with demonstrate and impact having Our action is clinical of growing. that mechanism its strong is

of Our most use. compelling other And differentiated products. IBS-C launch is reason demonstrates surveyed compared of to research is for two-thirds action unique the over for tracking prescription majority, that its mechanism IBSRELA hospitalized report GIs the

These repeat align December Spherix also are their with and prescriptions as we IBS-C GIs surveyed new and consistent in growth of The candidates reflected note the insights patients refill report as with good XXXX prescription, both new well that XX% consider writers. be seeing for treatment. in to approximately

Our salesforce an making presence is clearly impact.

are set initiatives working. IBSRELA that have omnichannel a typically clearly existing an clearly IBSRELA policies impact patients grant option. Payers if strategy evaluated with access authorization, Our and an been making to and our have access treated market is by prior

therefore, authorization the treated IBS-C care limited the if writing more, and prior are have one, of patients approvals secured. these high criteria, these with being The options been commonly under available, meet not of doctors

patent responding position landscape Patients that suggest key market candidates strong what for favorable across launch agent the to are view across are there in the a as and we life identified new continue increasingly indicators in no is favorably advance the to market share These for a to treatment. being are IBSRELA, accessing our branded drug, where IBSRELA.

across Transitioning now planning XPHOZAH, commercial briefly opportunity and market XPHOZAH. market to dynamics will I the our for hyperphosphatemia background for the review

Published over available the condition dialysis. CKD treatment to class with a guideline-directed phosphate binders treat consistently on XX% single patients this to prevalent of six-month data levels highly established in despite with target unable demonstrates period, of therapy are that patients active maintain

is hyperphosphatemia It alternative. is a of next-line need clear great in that

and XPHOZAH, With a patients inadequately with of controlled will phosphate new binders have launch the alternative. approval

XPHOZAH, this a a one absorption reduction via approach pathway of that treating dosing phosphate blocking Tac-sized absorption represents absorption. phosphorus patient to is population. clinically hyperphosphatemia enables It by and a primary provides Tic day twice to phosphorus resident the of novel a meaningful pill first-in-class unique inhibitor

of indicated and surveyed market a nephrologists large product many level XXXX, proposition adopt would intent a patients XPHOZAH high level XPHOZAH. consider candidates of and in Spherix opportunity to among In high by has addition, of December nephrologists, subset research The Ardelyx. of a for to interest for parallels

patients established being looking are entering treatment A not for those by their first-in-class an patient that healthcare mechanism bring to group a that's actively novel single providers currently meeting prescription approaches of market concentrated And to patients. needs. therapy are treated with a option

and salesforce unable approximately important blocking guideline currently XX% we to will phosphate a providers focus on that can healthcare centered helping a on XPHOZAH, positioning hyperphosphatemia patients drugs the many dedicated launch X,XXX target role prescription, play all are nephrology levels. established who with of for To in product of mechanism achieve the nephrology account

commercial closer get launch to established activities to enabled quickly a a once are we ramp mobilized have Our poised and rapidly planning we nephrology launch dedicated capabilities salesforce date. up

the leadership ongoing nephrology stakeholder landscape. enabling and experience, commercial Our peaked team nephrology leader key engagement has the opinion across

launch second XPHOZAH XXXX, commercial, If it Medicaid, Part of comprised sometime traditional half prescription in and and of into the Medicare launched model VA will payer payers. approved is D, a

driven controlled binders therapy centers for and level novel unique phosphate on the prescriber mechanism position adopt demand XPHOZAH high hold treatment new their by motivation a option. access strategy will of Our as inadequately a patients by

For and only option. this differentiated need, large XPHOZAH new subset offers of patients the in

we for authorization is areas prior where available, are introduced require the all expect low-cost access to established therapeutic case options payers will XPHOZAH. therapies As a into for innovative branded

controlled. this CKD We expect dialysis access. in inadequately patients do with hyperphosphatemia cases, majority actively with many phosphate and patient therapy not binder are treated on of to The limit

achievable. prior meeting Therefore, will criteria authorization be

In addition, IBSRELA and program for services This will working to Ardelyx access affordability. work a patient strategy will that a through designed optimize for comprehensive and XPHOZAH. is provide is support

price While pricing to announce for current ready not XPHOZAH, are the characterize landscape can I launch the for the space. hyperphosphatemia in you we

phosphate XX to treated landscape XX% ranging with are point a $X,XXX from launched proposition. majority the clinical points provides of opportunity binder, with pricing dialysis current per month. are This years list with last its available launch within price branded per phosphate-lowering binder While XPHOZAH price at requiring approximately aligned value treatment to month $X,XXX patients generically for the

of own biotech its Across is the companies commercializing class landscape, products. the actively unique Ardelyx in

launch position half market and at the our second in advancing are of XXXX. potential preparing XPHOZAH IBSRELA for of We the

realized novel mechanism commercial The success dynamics are by product, developed are the for Ardelyx powered market, state our reflects first-in-class disruptive our with innovative our two in products. therapy discovered competitive commercial by poised for vision and business of strategy and being therapies these favorable

a as momentum and Ardelyx the position eliminate commercial strong IBSRELA company. XPHOZAH, for results our of promise portfolio commercial of XXXX going QX assets market potential the strong growth build with successful into Our for combined to biotech for

I will Justin now XXXX turn quarter it our walk year to fourth through to and end over financials.

Justin?

Justin Renz

we're Thank into you, expenses through I'm and turning collaboration position you how XXXX. about product going our cash walk our and to thinking Susan. sales, revenue, before

We significant million figure third quarter. of in net of XX% sales year $X.X $XX.X from sales the That net million. had $X.X growth, we full and product reported the fourth for what IBSRELA quarter of million increase sales reflects quarter-over-quarter a in

of under payments is dialysis. agreement recognized year This to compared improvement million a the related of drug license October. partner which adult in payments KKC, full milestone also in in in November million Japan XXXX, We earned in application of tenapanor and $XX for for in $XX.X the on in the $XX.X payments submission amendment with between patients and Ardelyx hyperphosphatemia and came upon $XX KKC's million to of collaboration million new our CKD during the was XXXX revenue our XXXX to

the quarter ended Research and development expenses compared the to from same for XXXX year. $XX XXst, million quarter December million were $X.X last

research the XXXX. and decrease compared full year to XX% were year million, expenses the $XX.X For XXXX, of full a development

primarily The and elimination clinical the the result with from is lower function lower our fourth lower of decrease research we quarter in capitalize from of IBSRELA those began study to costs study, our the of expenses inventory, R&D expenses XXXX. optimized as tenapanor manufacturing the expenses associated costs

for million $XX.X the in to XXst, $XX.X increase XXXX. million were quarter compared XXXX, ended expenses December of $X.X administrative fourth quarter the and general, Selling, an of the million

in to XXXX. Full SG&A compared expenses was launch of X% increase IBSRELA were million XXXX. year in the primarily due with an the to $XX.X XXXX, costs The associated increased increase of

diluted the XXXX, net Due of share. million aforementioned XXst, income approximately fully December $X.XX ended for quarter or to the payments we per $XX had KKC

Net loss $X.XX share XXst, compared or December was for million the loss of year XXXX a share to or ended in per XXXX. $XXX.X net $X.XX $XX.X million per

as million cash investments the year cash, previous of of total had equivalents, and $XXX.X As XXst, short-term short-term $XXX.X investments to total end. we and compared December cash equivalents, XXXX, of million cash,

to making to a cash importance seek the sheet continue position. and we our recognized opportunities strong balance of We strengthen

approximately XXXX, release, As appeal we New in press $XX million from have of the you $XXX in Office stock which from of saw following our of million ATM includes program the as January our cash we Drugs. common letter unaudited raised the granted sale February of XX, under XXXX,

continue including for partnerships we IBSRELA of international to we pursue open capital non-equity As ahead, strategy territories solutions, will and look and XPHOZAH. ongoing

efforts will These seek approved. commercial for the while XPHOZAH uptake Susan to team IBSRELA, market if from we revenue drive and continue, rapid grow and

We to decisions to will continue maximize thoughtful make value. shareholder

is hyperphosphatemia $XX Japan. NDA the this we revenue quarter additional additional reminder, milestone year. of of collaboration we fourth capital approved, approval Royalty tenapanor in and the for and one non-equity a expect million pending if an KKC Combined, Partners As from KKC's XXXX in expect Healthcare of later

ahead, have in to As to confidence our our ability fund operations. we look we continue

I some we the the Mike comments call will open call now back concluding to turn questions. for Mike? before for

Mike Raab

Thanks Justin.

advancements launch heard, our you for third process CRL our successfully the commercialization in earnings for forward and in of resulting subsequent a made November, second our year. of concluded significant we half a on and of the and in appeal As XPHOZAH, accomplished appeal call the providing this quarter granting approval XXXX. Since in path we've IBSRELA lot

report, our our to our that issued commitment which are Ardelyx's also We first-ever demonstrates to ESG all critical of stakeholders. issues

a is of for future will commitment and groups to these and be our thank to the has point foundation that clinician It gotten I team us the communities. steadfast and patient want this the Ardelyx's success.

I that, to open now questions. will With call the Jamie?

Operator

the Ladies question-and-answer begin and [Operator gentlemen, session. at Instructions] this we'll time,

comes today question go question. first Laura Please Chico our your from ahead And from Wedbush. with

Laura Chico

opening Thanks I missed for runway? but the comment question. could progress. taking this remarks, Congratulations have One, for very Good cash the on I the much the might on think expectation you afternoon. in latest

able be And there's then meaningful Thank any this would secondarily, at off-label with point? if you occurring utilization to comment IBSRELA you.

Mike Raab

Yes.

of question that whole I'll the anticipate information, Let first, hand we obviously me part Justin. the lot off-label very to a use. second don't of over then much kind don't address We of see it

get that you've off-label Remember by which to these that NDAs, hopefully strategy the that to it separate different the relates NDC codes, different we we two very think different -- is approved, undertook markets, IBS-C. helps as drugs outside both any dosing, sent

IB I Within tablets dosing the think our is XX data that can of the where mg the IBS-C, demonstrates get you best effect.

very So, that. much we don't of see

Justin?

Justin Renz

Thank you, Yes. Mike. Laura. Hi,

February has managing cash, as company investments be XXth, to about mentioned, many targeted-approach And million. going we're as leverage of I equivalents, on very short-term solutions continue how total finance As we thoughtful and and had and to that cautious $XXX cash be the we our possible approximately spending, as Susan non-equity unaudited of led.

our any We're future but on operations. ability going our fund guidance our to specific give financing in confident we're runway, not to or

Laura Chico

guys. much Thanks very

Mike Raab

Laura. Thanks

Operator

question Please ahead Citi. from next Yigal our go question. your with comes And from Nochomovitz

Yigal Nochomovitz

the conclude would the that for made with A meeting curious Hi, question. regard just be or that happen it review? team. to a anything I'm that did two-month meeting, in Type Mike Thanks a closer you and to six-month taking

Mike Raab

And think expecting if quicker than that why that's months, Yigal, certainly I will it our base we continue perspective could No, it be we But base us sooner. that. have to could for be to case prudent we share. six is it's be get that case, that our

Yigal Nochomovitz

details what what with the any in to And needs terms resubmission, you is NDA there? Okay. provide to required to then regard complete of are able happen to more

Mike Raab

with have is additional think pretty to is we we safety, but done know I it to work anything be update I'll add? needs Rob comment, straightforward. as to to -- I generally, Rob, think ask

Rob Blanks

that that it, think initial well submitted you two include safety safety we Mike. our and I NDA need you know, partners of covered Chinese we as from after have It's and trials data the as a mostly data, as to completed a of studies lot lot we Japanese we

Yigal Nochomovitz

Great.

you. Thank Okay.

Operator

question. Howerton comes go Please next ahead Jefferies. Chris Our question with from from your

Unidentified Analyst

on This to provide And stable? first My gross is is question is details A.J. net? for some IBSRELA's you could Chris. it

Mike Raab

Justin? Yes,

Justin Renz

Yes. Thank already filed you'll the A.J. you, provided see information we our XX-K today, there. Yes,

general between premise range operations, XXXX through we a XX% As our and of the XX%. course

see reduction. as You'll XX% ended year approximately we were a XXXX, for the

So keep how price. gross general XX% a to of XX% you net scoring depending or

Unidentified Analyst

you. Got

you. Thank Okay.

Okay. question months? here My next possible is, process there to risk delay is a the of any review in six terms beyond

Mike Raab

on way we the year. The says But this. we're appeal to solid NDA to So The half we we very approved. division on that with a as should establishing look the path way are that it of a work a you the in granted to been approval. the us launching label drug bit about to know, to that the path us this the jaded in we're second in is instructions at have think says

interaction that we of perspective. meeting A Type doesn't I think the change had that the any at

Unidentified Analyst

Fantastic. Okay.

you asking mind If one don't more question. my

Mike Raab

Go for it.

Unidentified Analyst

to hope but been given jumping have any you programs? to acidosis further on this when and thought going up [ph] the on gun, clean back start your you're I isn't

Mike Raab

No.

hearing think we're think national quite the our to we've We've got the our things with as about from we important and I capital. and remarkable. physicians about doing So and really finishing sales IBSRELA. the be pipeline, Justin very outlay just way enthusiasm our actually the meeting We're said, thoughtful that got field what of we're is

today. When capital, in to invest and to take by that to higher it like ourselves going getting be a does will So invest than approved. ability that we've focusing on thoughtfully, got then on path the assets sufficient we XPHOZAH our on priority other IBSRELA get wisely, we are have

Unidentified Analyst

an for congrats my you QX. questions excellent on taking thank Well, Fantastic. and

Mike Raab

A.J. Thanks,

Operator

go Kaplan question from with ahead from Ladenburg your Matt next question. Thalmann. Please comes Our

Unidentified Analyst

our as wondering for your just the if wondering I questions. in expectations visibility quarter. on XXXX? was on Raymond progressed, for I the had was is This Matt. Congrats Hi. launch has taking better you Thanks for

Mike Raab

Yes.

sharing it's numbers expect prescriptions Susan, And or total guidance to growth script too anything early getting for us in for of But terms be going not So, can XXXX. in we're we certainly. what in to patient be add that? to you

Susan Rodriguez

I are data, for a based Yes, momentum the time, seeing that at mean, ready direction to strong And little some understand guidance. really give We time clearly quarter-over-quarter. on prescription XXXX. no. the more ourselves to growth we be we'll need

Unidentified Analyst

guess, I you IBSRELA been ex-US enough. Okay. thought done Yes, do well? What as deals have you've you Europe was wondering about several fair about I -- for think potentially?

Mike Raab

Yes, no, certainly.

you territories if in of the think opening now way we're I those heard working on up a in getting capital. remarks, things are non equity as that of sources

IBSRELA So XPHOZAH will those efforts and in both China. for continue

As our in you done well see, with with KKC we've relationship Japan.

We have IBSRELA motive China. China XPHOZAH that right in the has done and both for both

world other opportunities. and all un-partnered So in the territories the are

Unidentified Analyst

Okay. are limiting just audit Cool. question may, X kind proposal, kind me, And I XXXX? second that What of for prepared for was the And if last half a the thanks. you in for of launch commercial the potential wondering. for I rate steps preparation

Mike Raab

Susan?

Susan Rodriguez

Yes.

our commercial we established patient as So, we distribution. infrastructure with have XPHOZAH, relates sales operations, it to the services, very mobilizing place of for AJ, marketing, are already preparations launch everything as in

of So to are already these XPHOZAH. be prepared all ramping aspects for the up of launch

stake the mobilize rapidly in in actual of and feet to to be understanding dedicated the networked We team, a are able on nephrology the have the a senior XXXX, preparedness well to the get a launch we force. as second sales level half date nephrology, get to have of across closer we country high ground in leadership well will

our in the executing schooled something we approach up are successfully experienced And So quite market well and narrative, we is with lined and to is as go that for everything IBSRELA. in mentioned, nicely. already

be in to ready falling very for it's So nicely line XPHOZAH.

Unidentified Analyst

Thanks.

Operator

comes Our Cowen. go Bohnsack Instructions] from Peyton ahead Please with next from [Operator question your question. TD

Peyton Bohnsack

just productive meeting, follow-up you for label Type quick truly Hi, question real did Joe. Peyton on eventual I've when a discussions? did this IBSRELA. labeling on Congrats And guess I Thanks this second thanks one. the year taking A any clarity look for engaged or got you then give and for guys like? additional on After questions. one the Or in I our would detailed about guess really

Mike Raab

stepwise right. It's Sure. approach, a

So re-file we need to NDA. the

that binder So from with you think But until we've from no as discussions be as to we've have OND, that our field shared labeling current an are interactions going well, it which our large I shared demonstrated data the for those and the of to that as failing benefit approved. therapies, take have a strength granted patients they're XPHOZAH is active ready NDA. once this majority

it's NDA. that know premature date have share discussions So file. get you will we -- we the we information that have will the until goal that have once And those filing share no, you labeling the post will to NDA -- we when

Justin Renz

information second need But, and additional required Peyton, we we the will growing our in complete can confirm have analyses that no submission quarter. to be we the

Peyton Bohnsack

script Awesome, know internal script research market proportion great. of of in kind of you were of then data, the if compared your initially patients just kind are any over I guess I that's prescriptions? kind refilling the said, after that IBSRELA was trying how you your of anything growing to numbers and data, med to of patients told new you on or about if but any I IBSRELA switching patient I to And launch, say to or going wondering,

Mike Raab

generally. Yes. I'll it comment ask on Susan

heard new refill and in I statement seeing you her think both growing we're that well.

data, some Susan, look TRxs and you or at anything as Symphony can the your NRxs add? that think own. you Akebia, assumptions to those both going on I data see draw could you're whether you

Susan Rodriguez

Yes. No, exactly.

and they we're feedback that, hearing very prescriptions. that in them the nice new writers, they're believe And experience a into going data. the IBSRELA very well we're and treatment IBSRELA, new is that reporting with is very with the on a the which rating So of per seeing that identifying nice seeing on repeat very need are the ground and between refill we're physicians relationship consistent patients top Spheris treating trend satisfaction

blocking as we're that not demonstrate momentum Mike script. really seeing in alluded strong to up the scripts. lining is And everything growth So to, we're

you a yourself. and access look would for of So take momentum that's and have see kind you this to that can something

Peyton Bohnsack

very Great. Thank you for our taking questions. much

Mike Raab

Thank you.

Operator

And questions. turn floor closing to I'm to no ladies and the gentlemen, management remarks. for additional I'd any over like showing back

Mike Raab

again potential. questions our reiterate joined Ardelyx a everyone and behalf company I important executing and On of Thanks is innovative to that optimism about the our about team, call. we're want opportunities is, Ardelyx the to commercial I lie to today's are who spanning unique strategy that excited and therapeutics, on of ahead. development an as and said, the replicable and discovery future we

to again, forward their Jamie. Once want dedication sharing call. months thank team to and tireless we the close for ahead. With I you, to Thank more that, helping look can patients. We weeks the the in

Operator

And with thank that, conference and you We we'll joining. today's call for conclude presentation.

lines. now may You your disconnect

Ardelyx (ARDX) 2 Mar 232022 Q4 Earnings call transcript